Agenus Inc revenue by segment AGEN

Annual Quarterly

Agenus Inc splits its revenue into 11 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Non Cash Royalty Revenue Related To The Sale Of Future Royalties at $108.6 million, 95% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	134	114	103	156	98	296	88	150	37	43	23
Non Cash Royalty Revenue Related To The Sale Of Future Royalties	—	109 +7.5% share 95.1%	101 -11.9% share 97.6%	115 share 73.3%	—	44 -6.7% share 15.0%	48 share 53.9%	—	—	—	—
License Fee Revenue	—	—	—	25 +400.0% share 16.0%	5 -97.7% share 5.1%	220 +862.5% share 74.4%	23 -69.7% share 25.9%	76 share 50.3%	—	—	—
Royalty Sales Milestone	—	—	—	—	—	—	—	15 share 10.1%	—	—	—
Recognition Of Deferred Research And Development Revenue	—	—	—	12 +28.1% share 7.8%	10 -57.3% share 9.7%	22 +81.7% share 7.6%	12 share 14.0%	—	—	—	—
Pre Commercial Product Revenue	—	4 share 3.7%	—	—	—	—	—	—	—	—	—
Manufacturing Facility	—	—	—	—	—	—	—	3 share 2.2%	—	—	—
Research And Development Services	—	—	—	1 -14.4% share 0.9%	2 +13.6% share 1.7%	1 +95.8% share 0.5%	1 -55.8% share 0.9%	2 share 1.1%	—	—	—
Revenue	—	1 -48.3% share 0.9%	2 -32.7% share 1.9%	3 -71.7% share 1.9%	11 +56.8% share 10.7%	7 +45.1% share 2.3%	5 share 5.2%	—	—	—	—
Research And Development Revenue	—	0 -30.7% share 0.3%	0 share 0.5%	—	—	—	—	—	—	—	—
Product And Service Other	—	—	—	—	—	0 +102.2% share 0.1%	0 share 0.1%	—	—	—	—
Grant	—	—	—	—	—	0 +102.2% share 0.1%	0 -93.2% share 0.1%	1 share 0.9%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: AGEN (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Lexington, MA
SEC filer status: Accelerated filer, Smaller reporting company
SEC CIK: 1098972
Former names: ANTIGENICS INC /DE/ (until Jan 5, 2011)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.